Somnomed (SOM.AX) Stock Price
Somnomed Price
Revenue has compounded at 22.9% per year over the past 19 years to 114.53 M AUD. Earnings per share have grown at 11.5% per year over the last 8 years. Somnomed's net margin stands at -2.3%, up from -6.1% several years earlier. Analysts set a median price target of 1.01 AUD, implying 275.9% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Somnomed stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Somnomed business model & stock analysis
Frequently asked questions about Somnomed
The business model of Somnomed Ltd revolves around the manufacturing and selling of medical devices to treat patients with sleep-related breathing disorders such as obstructive sleep apnea (OSA). Somnomed specializes in creating oral devices known as mandibular advancement splints (MAS) that are worn during sleep to help keep the airway open and improve breathing. These custom-designed devices are crafted using dental impressions and are prescribed by healthcare professionals. Somnomed focuses on delivering innovative and high-quality solutions to help patients improve their quality of sleep and overall well-being.
Somnomed Ltd is primarily active in the medical device industry, specifically focusing on the treatment of sleep-related breathing disorders. With its innovative oral appliance therapy, the company provides effective solutions for patients suffering from conditions such as sleep apnea. As a leader in dental sleep medicine, Somnomed Ltd partners with healthcare professionals worldwide to improve the quality of life for individuals affected by sleep disorders.
The main competitors of Somnomed Ltd in the market include companies such as ResMed Inc., i3DiCAM, and Panthera Dental. These companies compete with Somnomed Ltd in the field of sleep apnea and dental solutions. ResMed Inc. is a leading global provider of medical equipment, focusing on sleep apnea and other respiratory disorders. i3DiCAM specializes in 3D imaging and CAD/CAM solutions for dental applications. Panthera Dental offers innovative dental sleep solutions and services. While Somnomed Ltd holds a strong market position with its range of oral devices and sleep apnea treatments, it faces competition from these established players in the industry.
Somnomed Ltd is a leading company in the dental sleep medicine industry. Established in 2004, it has become a global leader in providing innovative solutions for the treatment of sleep-related breathing disorders such as sleep apnea. With headquarters in Australia, Somnomed has expanded its presence worldwide, offering state-of-the-art oral appliances that improve patients' quality of life. The company has a strong commitment to research and development, continuously striving to deliver advanced technologies and improve treatment outcomes. Through its dedication to excellence, Somnomed has garnered a reputation for its high-quality products and undisputed expertise, making it a trusted choice for both patients and healthcare professionals.
Since its establishment, Somnomed Ltd has reached several significant milestones. The company has successfully developed and patented innovative medical devices, such as SomnoDent, which is widely recognized as a leading oral appliance therapy for obstructive sleep apnea. Somnomed Ltd has also expanded its global footprint, establishing a strong presence across major markets like the United States, Europe, and Asia-Pacific. Over the years, the company has fostered strong relationships with dental and medical professionals while continuously investing in research and development. With a commitment to improving the lives of patients suffering from sleep-related breathing disorders, Somnomed Ltd continues to drive innovation and deliver excellent treatment solutions.
Somnomed Ltd is primarily present in various countries and regions across the globe. The company has a strong presence in North America, including the United States and Canada, where it offers its innovative sleep apnea solutions. Additionally, Somnomed Ltd has established a significant foothold in Europe, catering to patients in countries such as Germany, France, Italy, and the United Kingdom. It also operates in the Asia-Pacific region, with key markets including Australia, New Zealand, and Japan. With its international reach, Somnomed Ltd continuously expands its presence to address the needs of individuals suffering from sleep-disordered breathing worldwide.
Somnomed Ltd represents values of excellence, innovation, and patient-centered care. With a strong corporate philosophy, the company is committed to improving the sleep health and quality of life for individuals suffering from sleep-related breathing disorders. Somnomed Ltd prioritizes the development and delivery of high-quality, clinically proven oral devices that provide effective treatment options for patients. By leveraging cutting-edge technology and a patient-focused approach, Somnomed Ltd aims to enhance sleep medicine and promote healthier sleep patterns worldwide.
Analysts currently set an average price target of 1.01 AUD for the Somnomed stock (median: 1.01 AUD), implying +275.9 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Somnomed stock: 6 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Somnomed share trades at 0.17 EUR (0.27 AUD).
The Somnomed share (SOM.AX) is listed on 4 stock exchanges, including: SIX (Zürich) (RJV.SW), ASX (SOM.AX), Frankfurt (RJV.F).
SomnoMed Ltd is a leading player in the field of sleep medicine and specializes in the manufacturing and distribution of sleep medical devices. The company was founded in 2004 and is headquartered in Australia. However, it has a significant presence worldwide in Europe, North America, and the Asia-Pacific region. The business model of SomnoMed Ltd is based on the development, manufacturing, and distribution of sleep medical devices for the treatment of sleep apnea and snoring. The company offers a wide range of products, including SomnoDent® devices, a recognized non-CPAP solution for the treatment of obstructive sleep apnea. These devices work by gently increasing the lower jaw and tongue to open the airway passage and alleviate snoring and symptoms of obstructive sleep apnea. The company collaborates with a network of medical device dealers and sleep medicine professionals to sell and distribute its products. SomnoMed Ltd also has excellent relationships with insurers and healthcare providers to ensure that the treatment of sleep apnea is covered by their devices. SomnoMed Ltd offers value-added services such as training and support. In Europe, the company maintains its own production facility in Germany to meet the demand of local markets for specialized devices. SomnoMed is also committed to expanding and improving its product range through continuous research and development activities. SomnoMed Ltd also has an online presence and offers various online tools to assist customers in finding a sleep medicine professional near them or reviewing their insurance coverage. The company has also developed online training to educate sleep medicine professionals and customer service representatives involved in the care of patients using the SomnoMed product range. The different divisions of SomnoMed Ltd include the sleep medicine segment and the healthcare segment. The company's sleep medical devices are primarily intended for the treatment of sleep apnea and snoring. The aim of these devices is to improve the patient's breathing during sleep and thereby increase their quality of life. SomnoMed Ltd is also involved in the field of dental sleep medicine, and its devices are prescribed by sleep medicine professionals and dentists. The healthcare segment of SomnoMed Ltd focuses on healthcare services and also includes the manufacturing and distribution of medical products. The company offers training and support for its products to assist healthcare professionals in their application and patient care. In the coming years, the company is expected to continue its expansion of geographic reach, product development, and collaboration with physicians and sleep medicine professionals. The focus is on expanding market share in sleep medicine through the development of innovative products and the expansion of the distribution network.
The revenue of Somnomed is 114.53 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Somnomed is -2.65 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Somnomed is currently -22.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Somnomed stock.
The price-to-sales ratio (P/S) of Somnomed is currently 0.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Somnomed stock.
The Eulerpool Quality Score for Somnomed is 5/10.
The ISIN of Somnomed is AU000000SOM1. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Somnomed is A0B7QA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Somnomed is SOM.AX. The ticker symbol is used to trade Somnomed shares on the stock exchange.
Somnomed stock
Somnomed Peer Group
Somnomed Ticker
Somnomed FIGI
All fundamentals and in-depth analysis of Somnomed
Our stock analysis for Somnomed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Somnomed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.